Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

被引：0
|
作者：
Jang Ho Cho
Hyun Ae Jung
Se-Hoon Lee
Jin Seok Ahn
Myung-Ju Ahn
Keunchil Park
Jong-Mu Sun
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Pulmonary adenocarcinoma; Epidermal growth factor receptor; Programmed cell death-ligand 1; Predictive factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1341 / 1349
页数：8
相关论文
共 50 条
  • [21] PD-1 inhibitors in patients with Hodgkin lymphoma
    Rossi, Cedric
    Casasnovas, Rene-Olivier
    EUROPEAN JOURNAL OF CANCER, 2022, 164 : 114 - 116
  • [22] Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
    Tseng, Jeng-Sen
    Wang, Chih-Liang
    Huang, Ming-Shyan
    Chen, Chung-Yu
    Chang, Cheng-Yu
    Yang, Tsung-Ying
    Tsai, Chi-Ren
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Tsai, Meen-Hsin
    Yu, Sung-Liang
    Su, Kang-Yi
    Wu, Chih-Wei
    Yang, Cheng-Ta
    Chen, Yuh-Min
    Chang, Gee-Chen
    PLOS ONE, 2014, 9 (09):
  • [23] Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
    Hwang, In Kyoung
    Paik, Seung Sook
    Lee, Seung Hyeun
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 158 - 168
  • [24] Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients
    Song, Peng
    Cui, Xiaoxia
    Bai, Li
    Zhou, Xiangdong
    Zhu, Xiaoli
    Zhang, Jian
    Jin, Faguang
    Zhao, Jianping
    Zhou, Chengzhi
    Zhou, Yanbin
    Zhang, Xiaoju
    Wang, Kai
    Wang, Qi
    Yu, Yao
    Zhang, Xiaoyu
    Bai, Chunxue
    Zhang, Li
    THORACIC CANCER, 2019, 10 (05) : 1303 - 1309
  • [25] Trends in clinical development for PD-1/PD-L1 inhibitors
    Yu, Jia Xin
    Hodge, Jeffrey P.
    Oliva, Cristina
    Neftelinov, Svetoslav T.
    Hubbard-Lucey, Vanessa M.
    Tang, Jun
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 163 - 164
  • [26] The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China
    Xiong, Yu
    Mo, Pingzheng
    Yan, Yajun
    Wang, Shan
    Zhuang, Ke
    Ma, Zhiyong
    Chen, Xiaoping
    Deng, Liping
    Xiong, Yong
    Deng, Di
    Zhang, Yongxi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [27] The efficacy of PD-1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study
    Sato, Ryosuke
    Kumai, Takumi
    Ishida, Yoshiya
    Yuasa, Ryota
    Kubota, Akinobu
    Wakisaka, Risa
    Komatsuda, Hiroki
    Yamaki, Hidekiyo
    Wada, Tetsuji
    Harabuchi, Yasuaki
    LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2022, 7 (06): : 1808 - 1813
  • [28] Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
    Macerola, Elisabetta
    Bruno, Rossella
    Prediletto, Irene
    Sensi, Elisa
    Chella, Antonio
    Landi, Lorenza
    Ali, Greta
    Fontanini, Gabriella
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1207 - S1207
  • [29] Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Nonesmall-cell Lung Cancer
    Jiang, Tao
    Liu, Hongcheng
    Qiao, Meng
    Li, Xuefei
    Zhao, Chao
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    CLINICAL LUNG CANCER, 2018, 19 (02) : E177 - E184
  • [30] The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis
    Kotecha, Rupesh
    Kim, Joseph M.
    Miller, Jacob A.
    Juloori, Aditya
    Chao, Samuel T.
    Murphy, Erin S.
    Peereboom, David M.
    Mohammadi, Alireza M.
    Barnett, Gene H.
    Vogelbaum, Michael A.
    Angelov, Lilyana
    Suh, John H.
    Ahluwalia, Manmeet S.
    NEURO-ONCOLOGY, 2019, 21 (08) : 1060 - 1068
12345